SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
NCT00002548
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma. PURPOSE: Randomized phase III tri... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/05/2015
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma
Register for Updates
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
NCT00002849
Completed
RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in treating patients who have primary systemic amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Multiple Myeloma
Register for Updates
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
NCT00555906
Completed
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® \[bortezomib\] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2015
Locations: University of Maryland, Baltimore, Maryland
Conditions: Multiple Myeloma
Register for Updates
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
NCT00060684
Completed
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2015
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
Register for Updates
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00033332
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2014
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
NCT00507416
Completed
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2014
Locations: Annapolis Oncology Center, Annapolis, Maryland +8 locations
Conditions: Multiple Myeloma
Register for Updates
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
NCT00991939
Terminated
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/02/2014
Locations: University of Maryland, Baltimore, Maryland +1 locations
Conditions: Immune Thrombocytopenic Purpura
Register for Updates
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00005977
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/19/2013
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
NCT01505088
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
03/28/2013
Locations: Wilmer Eye Institute, Baltimore, Maryland
Conditions: Anterior Uveitis
Register for Updates
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
NCT00002704
Completed
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
01/31/2013
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Leukemia
Register for Updates
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
NCT00050440
Completed
The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2013
Locations: Not set, Baltimore, Maryland
Conditions: Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Register for Updates
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
NCT00366834
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Baltimore, Maryland +1 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Register for Updates